Key features and details
- ATP synthase inhibitor
- CAS Number: 1404-19-9
- Purity: > 95%
- Soluble in ethanol to 10 mM and in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Product nameOligomycin, ATP synthase inhibitor
DescriptionATP synthase inhibitor
Biological descriptionATP synthase inhibitor. Blocks the proton channel (Fo subunit). Macrolide antibiotic.
R)- 22-Ethyl-3',4',5',6'-tetrahydro-7,11,14,15-tetrahydroxy-6'-[(2R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethyl-spiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-[2H]pyran]-3,9,13-trione (for Oligomycin A)
Molecular formulaC45H74O11 (for Oligomycin A)
Storage instructionsStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in ethanol to 10 mM and in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
2D chemical structure image of ab141829, Oligomycin, ATP synthase inhibitor
Oligomycin inhibits ATP-dependent adipogenesis in 3T3-L1 cells.
Cells were induced to undergo adipocyte differentiation (A-D) for 5 days. Different concentrations of Oligomycin (ab141829) were then added (B, 1 µg/ml; C, 2 µg/ml and D, 10 µg/ml). After 10 days, the cells were stained with Oil Red O and visualized under light microscopy.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab141829 has been referenced in 11 publications.
- Blancke Soares A et al. High-resolution spatiotemporal pHe and pO2 imaging in head and neck and oesophageal carcinoma cells. Cancer Metab 9:21 (2021). PubMed: 33947450
- Feng Y et al. Functional and Adaptive Significance of Promoter Mutations That Affect Divergent Myocardial Expressions of TRIM72 in Primates. Mol Biol Evol 38:2930-2945 (2021). PubMed: 33744959
- Alexander RK et al. Bmal1 integrates mitochondrial metabolism and macrophage activation. Elife 9:N/A (2020). PubMed: 32396064
- Chatterjee N et al. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Rep 28:2317-2330.e8 (2019). PubMed: 31461649
- Kurihara Y et al. Chlamydia trachomatis targets mitochondrial dynamics to promote intracellular survival and proliferation. Cell Microbiol 21:e12962 (2019). PubMed: 30311994